Comparative Pharmacology
Head-to-head clinical analysis: PARADIONE versus TEGRETOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PARADIONE versus TEGRETOL.
PARADIONE vs TEGRETOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Paradione (paramethadione) is an oxazolidinedione anticonvulsant that suppresses neuronal activity in the motor cortex by increasing the threshold for repetitive neuronal firing and reducing synaptic transmission. Its exact mechanism is unclear but involves modulation of T-type calcium channels and enhancement of GABAergic inhibition.
Voltage-gated sodium channel blocker; stabilizes neuronal membranes and inhibits repetitive firing. Also inhibits glutamate release and enhances GABA activity.
100 mg orally three times daily; maximum 600 mg/day.
Initial: 200 mg orally twice daily; increase by 200 mg/day at weekly intervals. Maintenance: 800-1200 mg/day in 2-4 divided doses. Maximum dose: 1600 mg/day. Extended-release: 200-400 mg twice daily.
None Documented
None Documented
12-24 hours (terminal); prolonged in renal impairment
Single dose: 25–65 hours (mean ~35 h); chronic therapy: 12–17 hours due to autoinduction; clinical context: requires 3–4 weeks to reach steady-state after dose adjustment.
Renal: 70% unchanged; biliary/fecal: 25%; metabolic: 5%
Primarily hepatic metabolism; ~72% excreted in urine (as metabolites, <2% unchanged), ~28% excreted in feces via bile.
Category C
Category C
Anticonvulsant
Anticonvulsant